Linalool / P53 Cancer Research Results

LIN, Linalool: Click to Expand ⟱
Features:

Linalool — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile terpene found in many essential oils, including lavender, coriander, basil, rosewood, and citrus-associated oils. It is formally classified as a small-molecule phytochemical / monoterpenoid fragrance and flavor compound, commonly abbreviated as LIN or Lin. It exists as enantiomers with different odor profiles and biological handling. In oncology research, linalool is best treated as a preclinical bioactive terpene with in-vitro and limited animal-model anticancer signals, not as a clinically validated anticancer therapy.

Primary mechanisms (ranked):

  1. Induction of apoptosis through intrinsic mitochondrial and extrinsic death-receptor pathways, with caspase activation and reduced proliferation markers.
  2. Cell-cycle arrest and suppression of proliferative signaling, including Ras/MAPK and PI3K/Akt/mTOR-associated axes in selected cancer models.
  3. Oxidative stress-mediated cancer-cell killing, including cancer-selective hydroxyl radical generation in colon cancer models.
  4. Autophagy modulation, usually linked to Akt/mTOR suppression, but interpretation is model-dependent and not yet clinically established.
  5. Anti-migration / anti-metastatic effects in lung cancer cell models at high in-vitro concentrations.
  6. Anti-inflammatory and neuroactive effects, relevant mainly to symptom-support or non-cancer contexts rather than direct tumor cytotoxicity.

Bioavailability / PK relevance: Linalool is volatile and lipophilic, with systemic exposure possible after oral, inhaled, and transdermal routes, but therapeutic plasma levels for anticancer effects remain uncertain. Human oral PK methods have been developed, and inhalation/transdermal studies support absorption, but most anticancer experiments use concentrations that are difficult to map directly to achievable human exposure.

In-vitro vs systemic exposure relevance: Many anticancer studies use high micromolar to millimolar linalool concentrations, especially in lung, liver, leukemia, prostate, and colon cancer cell models. These levels may exceed realistic systemic exposure from food, fragrance, aromatherapy, or ordinary essential-oil use. Direct anticancer interpretation should therefore be concentration-constrained.

Clinical evidence status: Preclinical. Linalool itself has no established cancer-treatment indication. Human studies involving linalool-rich essential oils or aromatherapy are mainly supportive-care studies for anxiety, sleep, pain, or procedural distress, not tumor-response trials. Regulatory status is primarily as a flavor/fragrance substance, not as an approved oncology drug.

Linalool Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Intrinsic and extrinsic apoptosis ↑ caspase signaling; ↑ apoptotic fraction; ↓ Ki-67 and PCNA in prostate xenograft model Less defined; cytotoxic selectivity is model-dependent G Programmed cancer-cell death Core anticancer mechanism across several models; strongest translational signal is still preclinical.
2 Cell-cycle arrest ↑ G0/G1 or G2/M arrest depending on model; ↓ proliferation Context-dependent G Growth suppression Observed in leukemia, cervical, liver, and other cancer-cell studies; phase specificity varies by cell type.
3 PI3K Akt mTOR signaling ↓ Akt/mTOR-associated survival signaling; ↑ apoptosis/autophagy linkage Not well established R/G Survival-pathway inhibition Mechanistically plausible and reported in HepG2 and other models; one colorectal paper on Akt/mTOR and JAK2/STAT3 was later retracted and should not be used as support.
4 Ras MAPK signaling ↓ Ras/MAPK-associated proliferation signaling in HepG2 model Context-dependent R/G Reduced proliferative signaling Important in liver cancer-cell data but not yet a universal linalool mechanism.
5 Cancer-selective hydroxyl radical generation ↑ hydroxyl radicals; ↑ apoptosis in colon cancer models Proposed relative selectivity, but exposure margin uncertain R/G Oxidative cytotoxicity Useful ROS-related mechanism; should be listed as pro-oxidant cancer stress rather than antioxidant activity.
6 Mitochondrial stress ↑ mitochondrial apoptotic signaling; altered Bcl-2 family / caspase cascade in selected models Potential normal-cell toxicity at high concentration R/G Apoptosis amplification Best treated as part of apoptosis rather than a separate mitochondrial-targeted drug mechanism.
7 Autophagy modulation ↑ autophagy markers or autophagy-apoptosis interaction in some models Not well defined G Context-dependent death or stress response Autophagy may be pro-death or adaptive depending on model; avoid over-ranking unless specific cancer data support it.
8 Migration and metastasis behavior ↓ wound closure / migration in A549 cells at high concentration Not established G Reduced motility Potential anti-metastatic signal, but mainly high-concentration in-vitro evidence.
9 Inflammatory signaling ↓ inflammatory mediators in non-cancer inflammatory models; cancer relevance indirect May reduce inflammatory tone in some normal-tissue contexts R/G Supportive or microenvironmental modulation Relevant to aromatherapy/supportive-care context more than direct tumor killing.
10 Clinical Translation Constraint High in-vitro concentrations may not be clinically achievable Oxidized linalool can cause contact allergy; essential-oil exposures vary widely G Limits therapeutic extrapolation Major constraints are volatility, low water solubility, formulation dependence, variable systemic exposure, and lack of oncology efficacy trials.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
6480- LIN,    Linalool Induces Cell Cycle Arrest and Apoptosis in Leukemia Cells and Cervical Cancer Cells through CDKIs
- in-vitro, lymphoma, U937 - in-vitro, Var, HeLa
TumCD↑, TumCCA↑, P53↑, P21↑, p27↑, p16↑, CDKN2C/p18↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

CDKN2C/p18↑, 1,  

Cell Death ⓘ

p27↑, 1,   TumCD↑, 1,  

DNA Damage & Repair ⓘ

p16↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:410  Target#:236  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page